Genome-wide association studies (GWAS) have proven to be a highly useful design in revealing the genetic basis of complex diseases, for example in cardiovascular medicine. At present, most of the GWAS are studies of a particular single disease diagnosis (e.g., coronary heart disease, asthma etc.) against controls.
Introduction
Genome-wide association studies have proven to be a highly useful design in revealing the genetic basis of many complex diseases, and has contributed to the understanding of the mechanisms of many diseases, for example in cardiovascular medicine and psychiatry 1, 2 . GWAS data also have the potential to be directly translated to clinical practice, for example in risk prediction by polygenic scores, disease subtyping and drug discovery [3] [4] [5] [6] [7] [8] .
To date, more than 4000 GWAS have been conducted to date (https://www.ebi.ac.uk/gwas/), and the emergence of large biobanks (such as the UK Biobank) has further boosted the variety and amount of genomic data available. Most of the GWAS (or human sequencing studies) are studies of a particular single disease (e.g. schizophrenia, coronary heart disease, asthma etc.) against controls. However, in clinical practice, an individual patient often has more than one condition/disorder. For example, patients with coronary artery disease (CAD) are often comorbid with diabetes mellitus (DM), while DM patients often have obesity; in psychiatry, patients with schizophrenia have a higher probability of having comorbid substance abuse, depression, obsessive compulsive disorder and many other psychiatric disorders 9 .
Patients with both DM and CAD, for example, might share different pathophysiology than patients with DM alone or CAD alone. Viewed in another way, patients with both DM and CAD may be considered a 'distinct' entity, and its etiology and genetic basis may warrant further investigations. Ideally, we would perform a GWAS with 'cases' defined as patients having both disorders, and compared their genotypes with control subjects. However, recruiting patients with both disorders is usually more costly than recruiting those with a single disorder.
Along a similar line, it is often clinically meaningful to study patients with one disease but without a comorbid condition. For example, more than 90% of DM patients are overweight 10 ; however there are still DM subjects with normal weight, who may represent a specific subtype of DM. In the ideal case, we will wish to recruit patients with DM but normal weight as 'cases' and compare them against controls. However, the complexity and cost of recruitment is then increased (compared to the standard design of DM vs controls), hence limiting the practicality of such studies. As another example, it was estimated that ~75% of patients with depression also suffer from anxiety disorders 11 ; however, the rest of the patients having depression but no anxiety disorders may represent a specific 'subtype' of depression. By studying the genetic basis of such subgroup of patients, we will be able gain deeper understanding into the heterogeneity and pathophysiology of depression.
As raised in the above examples, many diseases are highly heterogeneous. Patients with the same diagnosis may have different clinical presentations and prognosis, and share different etiologies. Through stratifying patients of the same diagnosis by the presence or absence of comorbid condition(s) and uncovering the genetic basis for each subgroup, we may gain better insight into the pathophysiology of the disorder. This will ultimately lead to more targeted interventions or prevention strategies for distinct subgroups of patients with the same diagnosis.
The aim of this study is to develop a framework to decipher the genetic architecture of multiple diseases in combination. Specifically, we wish to uncover susceptibility variants for comorbid conditions, and for 'subtype' of a disease without comorbid condition(s) (e.g. DM without obesity/overweight, depression without anxiety, CAD without hyperlipidemia etc.). The framework can be potentially applied to any complex diseases, and only summary statistics are required, which greatly extends the applicability of the methodology.
In essence, we are 'mimicking' a case-control GWAS in which cases are affected with comorbidities, or affected by a particular disease but without a relevant comorbid condition (in either case, we may consider cases as having a 'subtype' of the disease as characterized by the presence or absence of comorbidities).
We will then apply such methods to cardiovascular disorders (CVD), uncover genes and pathways associated, and find out casual clinical risk factors for comorbid diseases (or disease without comorbidity).
This study is mainly focused on applications in cardiovascular medicine in view of its high public health importance 12 and that many CVD are related to each other; nevertheless, the method itself is widely applicable to any complex traits. The presented computational framework can be considered an extension of the method by Nieuwboer et al. 13 , for which the main focus was on finding susceptibility variants for functions of quantitative phenotypes such as body mass index (= weight/height 2 ). Here we modified and further developed the approach to accommodate binary outcomes, which are more commonly studied in GWAS, and proposed new applications in deciphering the genetic basis of comorbid disorders and disease subtypes as characterized by the presence (or absence) of a related trait. In addition, we also developed new methods to handle clinically defined categories of quantitative traits, approaches to compute covariance between phenotypes (which are required as input) as well as more general extensions to more than two diseases/traits.
Here we highlight a few related directions of research. One related research area is the finding of genetic correlation between complex traits. LD score regression (LDSR) is a commonly used technique to compute genetic correlation between traits, although there are also limitations to this approach, for example there are inherent assumptions that may not be fully fulfilled in practice. For example it assumes that distribution of causal variants in the genome is independent of the LD structure, and that (ideally) the variance explained by each SNP is the same. Also, if the SNP effect sizes are not normally distributed, the procedure may become less efficient, resulting in lower power to detect true associations 14 . Another related approach is to construct polygenic risk scores (PRS) for the first trait, and then test associations with the second. This approach however cannot easily accommodate sample overlap. There is a fundamental difference between LDSR or PRS with the approach presented here. LDSR/PRS aims to discover overall genetic correlation or overlap between disorders, but are not designed for finding specific susceptibility variants underlying comorbid disorders or a disorder without comorbid condition(s).
Another intuitive approach is to find variants passing a significance threshold (e.g. p<5e-8) for each trait, and directly find the overlapping variants. However, the setting of the significance threshold could be arbitrary, as setting a very stringent threshold (such as the conventional genome-wide significance cut-off) will lead to low power and carried the risk of missing genuine genetic variants contributing to comorbidity; setting a relaxed threshold (e.g. p<0.05) will result in increased false positive rates. Another approach to develop more formal statistical procedures to find shared genetic loci. For example, a co-localization approach based on summary statistics was proposed in Giambartolomei's paper 15 . The approach is Bayesian and outputs posterior probabilities that the variant is a genuine association signal for both traits. A limitation is that prior probabilities for different configurations of associations need to be specified, which may not be straightforward; difficulties may also arise for multiple independent associations at one locus. However, there are also fundamental differences between the 'co-localization' approach and our methodology. Our methodology can be conceptualized as mimicking the GWAS of a case-control study in which the cases are affected with comorbid disorders (or disease without a comorbid trait); as such, we are able to derive effect sizes [e.g. odds ratios(OR)] of individual genetic variants. We may conclude, for example, the allele A (compared to a) of a certain SNP confers an OR of 2.0 to comorbid depression and anxiety. On the other hand, we cannot derive effect sizes with the co-localization approach. Also, the presented method is based on the frequentist approach with p-values as measures of significance, which may appear more familiar to many biologists and clinicians. Since most GWAS analytic tools are developed based on frequentist methods or use p-values as input, it might be easier to perform secondary analysis (such as gene-and pathway-based analysis) with our methodology.
GWAS meta-analysis is another related topic. However, the principle of meta-analysis is different from the proposed approach which address genetic basis of combinations of diseases/traits. In a meta-analysis, we aggregate evidence from different studies of the same or highly related traits to improve power; if one variant is highly significant in one large study, the final meta-analysis result will likely still be significant, regardless of the results of other studies. In addition, meta-analyses are not designed for finding genetic variants for a disease without a comorbid condition, such as DM with no overweight/obesity 16 .
Method
In this study we introduce a statistical framework which has the potential to uncover susceptibility loci for comorbid disorders (or a disorder without comorbidity). It allows one to approximate the GWAS statistics for a comorbidity or a single disorder without comorbid trait based on the GWAS summary statistics of corresponding disorders only.
Here, we start by providing the derivation of GWAS summary statistics of interested trait (either a comorbid disorder or only single disorder without comorbidity) based on individual summary statistics. 
where is a × 2 matrix, is a × 2 matrix, is a 2 × 2 matrix, and is a × 2 matrix. We assume each row is independent and follows a multivariate normal distribution ~(0, ∑). If we have known the estimate for the matrix (denoted by ), standard errors of each , the covariance matrix between and , as well as the mean of these two phenotypes. This is equivalent to have the GWAS summary statistics of each phenotype and their phenotypic covariances. Our goal is to estimate , for the target trait(either a comorbid disorder or only single disorder without comorbidity), i.e., ( , ) = : = + +
2.2
where follows a normal distribution with zero mean. Obviously, it's equivalent to perform a GWAS for trait . To realize this, we use the second-order Taylor approximation of around the point ( ) for = 0, 1, 2 where ( ): = ( [ | = ], [ | = ])). Here point ( ) corresponds to the mean of the phenotypes of the individuals who has effect alleles on this SNP. The second-order Taylor approximation for the trait can be expressed as: 
2.4
Notably, the linearization is possible only if it meets certain conditions on the phenotype value space. To be more specific, division by 0 is not allowed. We can avoid this situation by linear transformation of the observed phenotypes and parameters in the matrix. If we neglect the minor errors incurred during the linearization process, we will have
Then we will have a direct approximation for when = 0, i.e.,
We can also estimate by evaluate it for = 1, 2 and weighting the results by their relative population frequency, i.e.,
2.7
Since we don't have the covariance matrix of , we need to estimate it between each of the . Based on our multivariate linear regression assumption, the corresponding covariance matrix of can be given by: 
2.9
Notably, the above equation only holds for completely overlapped phenotypes. If there is only partial overlap, , can be approximated as:
2.10
Where and are the number of individuals for the GWAS of and respectively, while ∩ , is the number of individuals both in the GWAS of and GWAS of . If ( , ) can't be directly calculated, we can use LD score regression to estimate ( , ) ∩ , based on GWAS summary statistics. Notably, if there is no sample overlap between the phenotypes, then ∩ , is zero, so is the term , . The covariance between intercepts , can be expressed as:
2.11
Since , is zero and ( , ) is negligible when sample size is large (typical GWAS sample sizes are >10,000 or more), the above equation can be simplified as:
2.12
Similarly, we get , = , = ̅ ,
2.13
A framework for application to binary phenotypes -uncovering the genetic basis of comorbid disorders or a single disorder without related comorbidity
The above derivations are based on continuous phenotypes. However, we are interested in disease traits which are usually binary. In this regard, we need to develop a framework to deal with binary phenotypes.
Conversion of coefficient (from logistic model to that under a linear model and vice versa)
In the above derivations it is assumed that we are dealing with coefficients obtained under a linear model.
However, summary statistics for binary traits are usually derived from logistic regression. We therefore need to convert the coefficients from logistic models to those derived under linear models.
Lloyd-Jones et al 17 proposed a method for transforming summary statistics based on linear regression to odds ratio( ): estimate from a logistic regression is unbiased regardless of a retrospective or prospective design, with any level of over-or under-sampling of cases. This property however does not apply for linear regression 18 . To ensure that the final effect size estimate is close to the actual estimate when a prospective study is performed, we shall use the population lifetime risk estimate for k. Intuitively the analysis is performed as if we were doing a prospective study in the population. In the final step we will convert the coefficient from a linear model back to a logistic coefficient, which we shall employ the lifetime time probability of the comorbidity [i.e. Pr(P 1 and P 2 )] as input for k.
As explained above, here we are also interested in the reverse of 2.14, i.e. solving for β 1 (coefficient under a linear model) given the odds ratio (OR). Denoting the odds ratio (OR) of SNP regressed on the binary phenotype by α, we have
2.15
We could solve the above quadratic equation for β 1. We choose the solution whose absolute value is smaller than the coefficient under a logistic model, i.e., ( ) < (log ( )). This choice could be verified by experimenting with different k and randomly generated p from uniform distribution with value range of [0.05,0.95]. As demonstrated by Fig.S1 , the absolute values of coefficient (β) for binary traits derived from a linear regression is smaller than the coefficient( ) under a logistic model, i.e., ( ) < (log ( )).
After the conversion, we may compute and . We can employ the delta method 19 to calculate the standard errors of and . In essence, the delta method can be used to quantify variance of a function based on its first-order Taylor approximation. Suppose ( ) and are the transform functions and mean vector of random variables = ( , , … ). The first-order Taylor expansion approximation for the function can be written as:
where ∇G(U) is the gradient of ( ). Then, we can take the variance of this approximation as the estimation for the variance of ( ), i.e.,
2.17
Covariance between the coefficients can be derived based on the methods described above.
Modeling comorbid disorders or a disorder without comorbidity
Let and be two different binary clinical traits (coded as 0 and 1 for the absence and presence of disease respectively), the presence of comorbidity (Comor) can be expressed as:
Thus we can infer the corresponding coefficient estimates as follows:
2.20
Similarly, having a disorder (P 1 ) but without a specific comorbidity (P 2 ) (e.g. CAD without DM) can be expressed as:
2.21
And the corresponding coefficient estimates can be estimated by:
2.23
Note that cov(P 1 , P 2 ) will cancel out in 2.20 and 2.23 hence this quantity does not affect the results.
Extension to more than two traits
The above proposed framework could also be extended to more than two traits. The only difference is that one of inputs should be the summary statistics of the comorbidity instead of a single disease, which could be derived from our proposed framework. For example, if we are interested in the genetic architecture of CAD comorbid with T2DM and obesity, we could estimate the summary statistics of CAD comorbid with T2DM first. Given the results, we could re-apply our methodology again to deal with comorbidity with the 3 rd trait (obesity). It is often difficult to extract the lifetime risk of more than 2 comorbid disorders from the literature.
If this is the case, we could employ Mendelian randomization (MR) to infer the OR of comorbid 1 st + 2 nd trait on the third one first, then the overall lifetime risk can be computed based on the methodology described in a section below. In a similar vein, the proposed framework can be applied to an arbitrary number of traits by sequential application of our method.
Application to clinically defined categories of quantitative traits
It also worth noting that our proposed framework is applicable to clinically defined categories of quantitative traits. For example, hyperlipidemia is a risk factor for many cardiovascular diseases and clinical thresholds for LDL-C, HDL-C and triglycerides have been defined to facilitate the identification and treatment for subjects at high risks. However, GWAS summary data are only available for lipids as a quantitative trait. One may wish to identify genetic variants contributing to for example comorbid CAD and hyperlipidemia, which is clinically important. To realize this, we need to transform coefficients derived from linear regression (with outcome as a continuous trait) ( ) to coefficients from logistic regression (with outcome as a binary trait, such as hyperlipidemia or not) ( ).
Suppose ~ ( = 2, ) is a binomially distributed SNP (where denotes the effect allele frequency,).
For each continuous trait , we may model the effects of each SNP by:
where  is an error term that follows a normal distribution. The variance of the error term can be given by :
2.30
Since individual SNP usually contributes to a very small explained variance, the residual variance of given is very close to the total variance of . For each SNP , we have:
2.32
Based on equation 2.29, we could compute the expected trait value for a given genotype, i.e.,
2.35
Where can be calculated by :
Given the genotype, the quantitative trait is assumed to follow a normal distribution. Since the mean [2.33 to 2.35] and variance [2.30, or approximate by var(y)] of the normal distribution are both known, we can infer the probability that the trait value will exceed (or fall below) certain threshold(s).
Then we could infer the corresponding odds for a clinically category (e.g. high LDL-C) for a given genotype, i.e., =
. To estimate the coefficient when clinically defined categories of a quantitative trait are considered as the outcome, we could evaluate the above at = 1,2 and weigh them by their relative population frequency, i.e.,
We may then use the delta method to calculate standard error of .
Computing probability of comorbidity P 1 and P 2
Our calculations require specifying the probability of comorbidity, ( ), for conversion of the linear coefficient back to the logistic scale in the final step of the algorithm. This measure is also required when the methodology is to be applied to three or more traits. While estimates could be obtained from related literature, the lifetime probability for comorbidity could be relatively hard to find.
If this is the case, we can calculate it from the OR (or relative risk, RR) of trait given the other trait (in which P 2 can be considered a risk factor). For example, one may obtain the OR of CAD given diabetes based on literature search or other means. Based on Bayes rule, we have:
2.25
Here we shall develop an approach to compute Pr( = 1| = 1) given OR or RR. Let f RF0 be the probability of having the disease (P 1 ) given the absence of the risk factor (P 2 ), f RF1 be the probability of having the disease (P 1 ) given the presence of the risk factor (P 2 ), P RF0 denote the probability of having no risk factor i.e. Pr(P 2 =0), and P RF1 denote the probability of having the risk factor i.e. Pr(P 2 =1).
From 2.25, we may also express ( ) as f RF1 x P RF1.
Note that we have = + • or
When the RR of disease given the risk factor is available, the calculation is straightforward as by definition Finally we can compute the probability of comorbidity by E(P 1 ,
Simulation study
Application to binary traits
To verify the feasibility and efficacy of our proposed framework, we simulated different sets of genotypephenotype data, with 300 SNPs (i.e. N snp = 300; coded as 0, 1, 2) and two binary traits. As the proposed framework is a SNP-based analysis, the number of simulated SNPs shall not affect the validity of our simulations. For each simulated SNP, the allele frequency was randomly generated from a uniform ) and all picked samples for each case-control study, i.e., = ( . + . ) 2 ⁄ . To adjust the overlap rate, we need to increase or decrease the number of common cases and/or controls for both traits. Two different overlap rates were simulated for both comorbid and single disorder. Notably, most shared subjects were controls as they were far more abundant than cases.
We also considered another type of study design, namely a prospective study of a population. The simulation scheme is similar to the above, except that the controls consisted of the rest of the population who were not cases. Again, we assessed the performance of our proposed method under different overlap rates.
We first simulated completely overlapped cohorts for traits A and B. Then we simulated 50% overlapped cohorts, i.e., 50% cases and controls for trait B were from the cohort for trait A. Besides, we studied the performance of our proposed framework both for the case where all required parameters were given and for the case where disease prevalence was misspecified.
Transforming regression coefficients for quantitative traits to those based on clinically meaningful categories
We simulated datasets to verify the feasibility of our proposed approach to 'transform' regression coefficients of quantitative traits to coefficients based on clinically defined categories. The number of studied subjects for quantitative traits was set to [50000,100000]. For each simulated SNP, the allele frequency was randomly generated from a uniform distribution from [0.05,0.95]. SNP-heritability was set to 0.1 and 0.2. The aim was to compare the theoretical estimates of regression coefficients and SE (based on summary statistics alone) against those obtained from simulated raw genotype data.
Application to binary traits in cardiovascular medicine
We applied our approach to 4 cardiometabolic disorders/traits, namely coronary artery disease 21 (CAD), type 2 diabetes mellitus 22 (T2DM), obesity 23 (BMI>=30) and stroke 24 (all types of stroke included), based on publicly available GWAS summary statistics. Details of these datasets are summarized in Table S1 . Since the effect size of individual SNPs in different GWAS may not correspond to the same allele, we employed the 'harmonise_data' function in the package TwoSampleMR (https://mrcieu.github.io/TwoSampleMR) which integrates GWAS summary statistics from different sources, taking into account DNA strand issues [25] [26] [27] .
Analysis was performed for SNPs with MAF>=0.01. In total, we studied the genetic architectures of 18 disease 'subtypes' (6 are comorbidities and the remaining 12 are 'single' diseases without relevant comorbid conditions) and identified contributing genetic variants.
Genes, pathway and cell type enrichment analysis
To better understand the functional and biological mechanisms underlying the genetic component of these disease 'subtypes', we computed gene-based significance using MAGMA inserted in the web-based tool FUMA 28, 29 . We employed false discovery rate (FDR) for multiple testing correction and selected genes that with FDR<0.05 for further analysis. Also, we performed "tissue specificity" analysis by examining whether the susceptibility genes are differentially expressed in a particular tissue. Apart from these analyses, we also conducted pathway analysis using the program "ConsensusPathDB", in order to unravel biological pathways that are unique to specific disease subtype and shared pathways among disease subtypes. Furthermore, we examined the cell types that are enriched for specific disease 'subtypes'.
Finding heritability explained by common variants
To further understand the genetic architecture of the 'subtypes' of complex diseases, we calculated their SNP-based heritability by LD score regression (LDSR) 30 . We also explored the genetic correlation between different disease subtypes with LDSR. Our aim is clarify whether disease "subtypes" are genetically different from each other.
Mendelian Randomization (MR) analysis
Mendelian Randomization (MR) is a methodology for inferring the causal relationship between risk factors and outcomes, using genetic variants as 'instruments' to represent the exposure. Here we performed two-sample MR in which the instrument-exposure and instrument-outcome associations were estimated in different samples. MR was conducted with 'inverse-variance weighted' (MR-IVW) 31 and Egger regression (MR-Egger) 25 approaches. One of the concerns of MR is horizontal pleiotropy, in which the genetic instruments have effects on the outcome other than through effects on the exposure. Note that MR-Egger is able to give valid estimates of causal effects in the presence of imbalanced horizontal pleiotropy. It could be assessed by whether the Egger intercept is significantly different from zero.
The IVW framework is widely used in MR. Here we used an IVW approach that is able to account for SNP correlations 31 . A similar approach may be used for MR-Egger, which allows an intercept term in the weighted regression. Please refer to 25 To ensure the robustness of our findings, we performed MR at multiple r2 thresholds (0.001, 0.01, 0.05, 0.1 and 0.15) and with SNP correlations taken into account. For simplicity, we mainly present the results at r2=0.05. However, as we shall present later, our findings are consistent across various thresholds and full results are given in supplementary table.
Only SNPs which passed genome-wide significance (p<5E-8) were included as instruments. We employed the R packages "MendelianRandomization" (ver 0.4.1) and "TwoSampleMR" (ver 4.25) for analysis. If a SNP was not available in the outcome GWAS, we allow using a "proxy SNP" provided r 2 >=0.8 with the original SNP. LD was extracted from the 1000 Genomes European samples.
Multiple testing correction
Multiple testing was corrected by the false discovery rate approach by Benjamini and Hochberg. The method controls the expected proportion false discoveries among the significant results.
Results

Simulation results
Simulation results for binary traits
Results of our simulation are presented in Tables 1 and 2. For more detailed simulation results, please refer   to Table S2 and S3. The correlations between the estimated and actual coefficients were in general very high.
Clearly, the correlation and RMSE improved with increased sample sizes and higher heritability explained by SNPs (i.e. with larger effect sizes of SNPs). Since current GWAS summary data are usually of very large sample sizes, often larger than 100,000, we believe the current method is sufficiently good to approximate the results from a GWAS of comorbid or other combination of diseases/traits. Also, the current method is valid under different rates of overlap between the input GWAS datasets.
In addition, it is obvious that the power increased with larger samples sizes (i.e., case sizes of corresponding traits) and heritability explained. The type I error is kept at or below 0.05 when results with p<=0.05 were considered significant. Interestingly, the power of the proposed analytic method is sometimes higher than the simulated actual GWAS with genotype data. This may be because only a small number of patients were affected with both diseases (N comor is low); on the other hand, the number of subjects affected with either disease is relatively larger, so the two sets of case-control GWAS data (of traits A and B) may contain more information than a GWAS on the minority who are affected by both diseases. Tables 3, 4 as well as S4 demonstrate the simulation results with misspecified population parameters for both comorbid and only single disorder. The proposed method is reasonably robust to misspecified population parameters. Simulation results for clinically defined categories of quantitative trait Table 5 demonstrates the simulation results for clinically defined categories of quantitative trait. Similar to binary traits, the correlation between estimated and actual coefficients are high. To be more specific, the correlation and RMSE improved with increased sample sizes and higher heritability explained by SNPs (i.e.
with larger effect sizes of SNPs). Considering current summary data for continuous traits are usually of very large sizes, often larger than 100,000, our proposed method is sufficiently good to approximate the results of clinically defined categories from a GWAS of continuous traits. 
Application to cardiovascular disorders/traits
The proposed framework was applied to 4 cardiovascular diseases/traits, the combination of which results in 18 disease 'subtypes' (6 are comorbidities and the remaining 12 are 'single' diseases without relevant comorbid conditions). We estimated the effect size (in terms of odds ratio comparing subjects with the disease 'subtype' versus those without) and the corresponding SE and p-values based on our presented analytic framework. Following the definition by the GWAS analytic platform FUMA, independent significant SNPs are defined as those that with p<5e-8 and are independent from each other at the default r 2 threshold (r 2 =0.6).
As for the definition of genomic loci, independent significant SNPs which are correlated with each other at r 2 ≥ 0.1 are assigned to the same risk locus. Then independent significant SNPs which lie within 250 kb are merged into one genomic risk locus. As for the lifetime risk of these involved diseases, some of them were directly extracted from relevant literatures [32] [33] [34] [35] [36] [37] , while the remaining were inferred from odds ratios (or relative risks) from relevant studies (see supplementary Table S5 ).
Genes, cell type and pathway analysis
Here we report the analysis results for the 18 disease 'subtypes'. In total, we identified 384 and 587 genomic risk loci respectively for 6 comorbidities and 12 disease 'subtypes' without a relevant comorbid condition ( Table 6 , Fig.1 and Table S6 ). Here we take Type 2 DM and obesity and the combination of these two traits as example. As expected, some susceptibility genes were shared among disease 'subtypes'. For instance, TCF7L2 and CDKAL1 38 are the top susceptibility genes for all 3 disease subtypes involving T2DM and obesity 39 It is also worth noting that TCF7L2 40-42 and CDKAL1 43,44 are also among the top genes for all three disease subtypes involving CAD and T2DM, suggesting a more general role of these genes in the pathogenesis of various forms of cardiometabolic abnormalities. Some susceptibility genes were only identified in specific disease subtypes. For example, FTO was found to be implicated only in disease subtypes 20 that involved obesity, i.e., obesity with or without T2DM, but not T2DM without obesity. This finding is consistent with previous studies that FTO mainly contributes to diabetes through its effects on BMI [45] [46] [47] .
Interestingly, BDNF was among the top genes for obese DM. BDNF treatment has been shown to reduce weight gain and glucose level in animal models and was also associated with glucose metabolism in clinical studies 48 . On the other hand, genes such as JAZF1, HMGA2, COBLL1, KCNJ11 and PPARG were ranked among the top for non-obese DM, indicating these genes may contribute to glucose dysregulation other than through effects on BMI/obesity. Notably, KCNJ11 and PPARG are also drug targets for sulphonylureas and thiazolidinediones (known anti-DM medications); further studies on the mechanisms and clinical efficacy of these classes of drugs in non-obese DM subjects may be warranted. For details about the concordant and discordant genes among disease subtypes, please refer to Table S7 .
In addition, we also performed pathway analysis through the tool ConsensusPathDB. The enriched pathways were summarized in Table S8 . Similar to gene analysis, some enriched pathways were shared among different disease subtypes while others were unique to particular disease subtype. Taking the 3 disease subtypes involving CAD and T2DM as example, statin pharmacodynamics, transcriptional regulation by RUNX3, and Angiopoietin receptor Tie2-mediated signaling were significantly enriched in all three disease subtypes, suggesting a boarder role of these biological pathways across CVD. There were also pathways that were only significantly enriched in certain disease subtype. For example, amb2 Integrin signaling 49 and chylomicron/plasma lipoprotein clearance 50 were top-ranked for non-diabetic CAD. As another example, adipogenesis and MAPK cascade pathways were enriched in CAD comorbid with T2DM. Previous studies have implicated a role of MAPK cascade in the pathogenesis of cardiac diseases and diabetes [51] [52] [53] .
By investigating the pathways enriched for each disease 'subtype', we hope to gain insight into biological mechanisms that are generally important across CV disorders, as well as more 'specific' mechanisms that may play a more salient role for certain disease combinations.
Next we also performed cell-type and tissue specificity analysis through FUMA. FUMA pre-computes a list of genes differentially expressed in different tissues (DEGs) from GTEx; input genes (significant genes from MAGMA analysis in GWAS) are then tested for enrichment for these DEGs. This approach is simple but differential expression does not always suggest causal role of the tissue. We consider this as a hypothesisgenerating analysis. According to the tissue analysis results, coronary artery and aorta were the most significantly enriched tissues only for disease subtypes that involved CAD. Interestingly, for disease subtypes including obesity without CAD, obesity without stroke and non-obese T2DM, the most significantly enriched tissues includes brain tissues such as cerebellar hemisphere, cerebellum and frontal cortex (Fig. S2 ). While the results will require further experimental validation, the brain has been suggested to play a key role in the control of body fat content and glucose metabolism 54, 55 .
Recently methods have been developed for cell-type enrichment analysis based on GWAS 56 , as single-cell sequencing data becomes more widely available. However, we note that single-cell data to date are more abundant for the brain than for other tissue types. This part is considered more exploratory as not all cell types are available for analysis in FUMA. We shall focus on the enrichment results for several comorbidities (most other disease combinations did not return significant results) . To highlight a few interesting findings (Fig. S3 ),
we found GABAergic neurons in the midbrain and prefrontal cortex to be the most enriched cell type for CAD with obesity. Interestingly, it has been reported that leptin exerts its anti-obesity effects mostly through GABAergic neurons in the brain 57 . GABA neurotransmission is also thought to play a role in appetite regulation 58 . On the other hand, GABA in the CNS may also regulate the sympathetic outflow to the coronary vasculature, causing a change in vascular resistance 59 . For CAD with T2DM, we also found enrichment of endothelial cells in the pancreas. 
Heritability explained and genetic correlation among subtypes
In order to uncover how much variance could be explained by all common variants in the GWAS panel, we calculated the SNP-based heritability of our studied disease combinations by LD score regression 14 . As 22 demonstrated in Table 6 , almost all comorbid cardiometabolic traits are more heritable than only single traits (without a comorbid disorder)..
We also assessed the genetic correlation between different disease 'subtypes' as defined by the presence or absence of comorbid conditions. The comparison results are summarized in Table 7 . Interestingly, many pairs had weak or moderate genetic correlations, implying that they are possibly distinct biological subtypes of the disease. For example, comorbid CAD/T2DM only has a weak genetic correlation with non-diabetic CA (rg = 0.111), indicating that they may be genetically and biologically distinct 'subtypes'. Similarly, only a moderate correlation was observed between obese CAD and non-obese CAD (rg = 0.232). Furthermore, we compared the extent of overlap of significant genetic variants among different pairs of disease subtypes. As expected, the weaker the genetic correlation, the lesser the overlap of significant SNPs between disease subtypes.
Genetic correlation and MR analysis
To further explore the genetic overlap between the studied disease subtypes and other cardiometabolic conditions (mainly stroke/CAD), we analyzed their genetic correlations using LD score regression (LDSR) ( Table S9 ). This is also clinically relevant as we are often interested in whether a certain combination of traits is a significant risk factor for a certain disease. For example, do obese DM and non-obese DM confer the same risk to CAD? The findings will have implications for management and prevention of CAD. Here we performed LDSR and MR on several selected traits with higher clinical relevance. Table 8 shows the results from LDSR. For example, we observed that similar genetic correlation between obese and non-obese DM with CAD, suggesting the extent of genetic overlap with CAD are similar. On the other hand, the genetic correlation between obesity (without T2DM) per se and CAD is relatively weak (rg = 0.0797). As another example, while T2DM with obesity is moderately genetically correlated with stroke (rg = 0.2779), obesity without T2DM has no significant genetic correlation with stroke.
We then performed further MR analysis for selected pairs of traits to assess causal relationships between several disease subtypes and cardiovascular outcomes ( Table 10 and S10). For simplicity, we primarily report the results at r 2 = 0.05, but most results are consistent across different r 2 thresholds. When focusing on CAD as the outcome, we found that obese DM is casually related to increased risk of CAD (MR-IVW; OR= 1.24, 95% CI: 1.16 to 1.33, p = 2.62E-11, Egger intercept p=0.355). Since we are studying binary exposures, the above OR roughly reflects the effect size with 2.72-fold increase in the exposure prevalence. Alternatively, the estimate may be multiple by 0.693 to reflect the OR resulted from doubling the prevalence of exposure 60 , which is presented in our tables. Similar results were observed at other r 2 thresholds and with MR-Egger.
Interestingly, we observed that obesity without DM does not have a significant causal link with CAD risks. On the other hand, non-obese DM showed no evidence of causal association under MR-Egger, but results were significant with MR-IVW. The Egger intercepts were significant (p<0.05 at all r2 thresholds), suggesting that there is imbalanced horizontal pleiotropy, and that results from MR-Egger are more likely valid. The above finding suggests that some genetic variants may affect both non-obese DM and CAD risks via different pathways, leading to association between the two traits but the link may not be causal.
When considering stroke as the outcome, most disease subtypes studied were significantly and casually related to increased stroke risks. An exception is obesity alone without CAD or DM, which did not show a causal relationship with stroke. It is also worthwhile to note that the effect size also differs across different risk factors. For example, CAD comorbid with DM confers a higher risk (OR~ 1.12 per doubling of exposure prevalence; r2 = 0.05) for stroke than DM without CAD (OR~ 1.03 per doubling of exposure prevalence) or CAD without DM (OR ~ 1.06 per doubling of exposure prevalence). If the Egger intercept p-value was <0.05, the Egger regression approach was used; otherwise we employed the MR-IVW approach which has better statistical power.
As discussed above, our analytic framework may also be applied to the combination of three or more traits.
To illustrate the methodology, we applied it to three cardiometabolic disorders, namely CAD, T2DM and obesity. Specifically, we explored the genetic architecture of obese T2DM comorbid with CAD, and nonobese T2DM with CAD. In brief, we applied the analytic method sequentially by first deriving the GWAS results of DM with and without obesity, then adding CAD as input in the next step.
Accordingly, we identified 76 and 91 genomic risk loci respectively for obese T2DM with CAD and non-obese T2DM with CAD that exceed genome-wide significance (Table S6 ). Details about gene and pathway analysis results were summarized in Table S7 and S8. Similar to our results above, many susceptibility genes and enriched pathways were implicated in relevant pathophysiological process for the involved cardiometabolic diseases, and some genes/pathways are shared between the subtypes while some are top-ranked for specific subtypes. For a brief highlight of the results, for example, TCF7L2 and CDKN2B were among the top susceptible genes for both disease subtypes, while BDNF and HMGA2 were only found to be susceptible in obese T2DM+CAD and non-obese T2DM+CAD respectively. As for pathways, plasma lipoprotein assembly, remodeling and clearance was one of the top enriched pathways unique to obese T2DM
with CAD while anti-diabetic drug potassium channel inhibitors pathway was only found to be significantly enriched in the other disease subtype, i.e., non-obese T2DM with CAD.
Application to clinically defined categories
Furthermore, we applied our proposed framework to low-density lipoprotein cholesterol (LDL) based on publicly available summary statistics with a sample size of 188,577 61 . Typically, a LDL cholesterol level reading of 190 mg/dL or higher is considered as very high in clinical practice. Following this standard, we transformed the summary statistics of quantitative trait into that of binary trait. Then, we uncovered the genetic architectures of disease combinations involved CAD and high LDL utilizing our proposed framework.
Totally, we identified 80, 40 and 65 genomic risk loci that exceed genome-wide significance respectively for CAD with high LDL, CAD without high LDL and high LDL without CAD. For details about these genomic risk loci, please refer to Table S6 . Genes and pathways analysis results were demonstrated in Table S7 and S8.
Analysis results suggest that identified susceptible genes and enriched pathways were strongly linked to the pathophysiology of involved disorders [62] [63] [64] . As for tissue specificity analysis, we found that liver was the most significantly enriched tissue for CAD with high LDL.
Discussion
Here we have presented a statistical framework to uncover susceptibility variants for combination of diseases/traits, based on summary statistics alone. The method is useful for revealing the genetic basis of comorbid disorders, or a disorder without comorbidity. More broadly speaking, the cases can be considered as those affected by as specific 'subtype' of the disease (as characterized by the presence or absence of comorbid traits). We also extended the methodology to deal with continuous traits with clinically meaningful categories (e.g. lipid levels), and to more than 2 traits.
There are several strengths and potential applications of the proposed framework. Firstly, as the method only requires GWAS summary statistics, our framework can be potentially applied to a large variety of complex diseases. This approach is likely more cost-effective than recruiting subjects with comorbid disorders.
As GWAS summary statistics with large sample sizes have dramatically increased these years, we believe the proposed framework represents a new paradigm and will open up countless opportunities to study the genetic basis and architecture of disease combinations. Such efforts will help shed light on heterogeneity and pathophysiology of different complex disorders, and may contribute to the identification of new drug targets and more personalized therapies. As for other clinical implications, different 'subtypes' of a disease may be related to different complications. For example, we found that obese DM is causally related to increased risks of CAD, but obesity without DM is not significantly linked to CAD. Similarly, LDSR also showed a weak genetic correlation between obesity with no DM and CAD. These analyses will help to refine causal risk factors for diseases and the formulation of prevention strategies. Note that other secondary analysis of GWAS summary data, such as transcriptome-wide association studies (TWAS), Summary-data-based Mendelian Randomization (SMR; based on eQTLs, methylation QTLs etc.), other SNP-based (partitioned) heritability estimation, pathway analysis approaches etc. may also be applied although we only illustrate the application of a few methods.
There are a few limitations to the current study. Similar to other methodologies that employ summary statistics from more than one sample, such as two-sample MR, there is an implicit assumption that both sets of summary statistics (assuming the study of 2 traits) are based on the same population. Large heterogeneity between the samples (e.g. different ethnic groups, large differences in inclusion/exclusion criteria etc.) may lead to inaccurate results. Also, most available summary statistics to date, including those we included in this study, are based on European samples. The results may not be transferable to other populations and it remains an open question how to accommodate summary data from different populations. While we believe the proposed framework is flexible and cost-effective, it could not completely replace the need to recruit subjects with comorbidities (or diseases without comorbidity). As discussed above, heterogeneity between study samples is inevitable, and recruitment of a more homogeneous sample with detailed phenotyping is still very valuable in uncovering the genetic basis of combination of diseases. While we highlights several genes and pathways underlying cardiometabolic traits, further experimental studies are required to validate the findings.
Taken together, we believe the proposed approach is a useful extension to conventional single-trait analysis.
Identification of genetic variants for comorbid disorders or disease 'subtypes' may ultimately lead to more targeted prevention and treatment, and identification of novel drug targets. Table S3 Simulation results for single disorder without comorbidity 
